trūFreeze® Spray Cryotherapy Patient Registry

Barrett Esophagus Clinical Trial

Official title: trūFreeze® Spray Cryotherapy Patient Registry

Status Completed

Clinical Trial Summary

To collect efficacy and outcomes data related to the use of trūFreeze® spray cryotherapy for the treatment of unwanted tissue in the pulmonary and gastrointestinal settings.

Clinical Trial Description

This is a prospective, multi-center registry of patients who are currently undergoing spray cryotherapy using the trūFreeze® device. The registry population consists of patients who are being treated using the spray cryotherapy trūFreeze® device for the removal of unwanted tissue, such as malignant or pre-malignant conditions in the pulmonary or gastrointestinal settings. Patients eligible to participate in the registry will have disease and treatment specific data collected throughout therapy and long-term follow-up. Subjects will be considered to have completed the registry when data from the 5 year follow-up visit has been collected. The beginning of the follow-up period commences with the first endoscopic treatment session. Subjects may be withdrawn prior to this for any of the following reasons: 1. Death, or 2. Lost to Follow-Up, or 3. Withdrawal of consent, or 4. Discontinuation by the investigator. Three attempts at contact using two different methods are required prior to determination that the subject is lost to follow-up. Attempts at contact must be with certified letters OR documented telephone contact. The registry will utilize electronic case report forms using a web-based platform housed at the University of North Carolina at Chapel Hill. Access to the database will be limited to individuals involved in the research registry and will require a unique user ID and password. All access to the database and web-based application will be encrypted (HTTPS) and electronic systems compliant with applicable privacy and security regulations. To maintain patient confidentiality, all subjects will be assigned a registry identification number, and this will be the only link between subject identity and treatment information. Read-only access will be provided to any personnel who is not an administrator or responsible for data entry. All data requested on the case report form must be recorded. All missing data must be explained. The system allows sites to directly enter data electronically, however sites are still responsible for ensuring they have source documents that support all data entered electronically that are separate and verifiable. The registry system will maintain an audit trail that captures when electronic entries are changed, what the change was, and who made the change. The investigators will ensure the capability for inspections of applicable registry-related facilities (e.g. pharmacy, diagnostic laboratory, etc.). The registry will be monitored by the sponsor, and allow auditing by the Institutional Review Board, government regulatory bodies, and University compliance and quality assurance groups of all registry related documents (e.g. source documents, regulatory documents, data collection instruments, registry data, etc.). ;

Related Conditions & MeSH terms

• Barrett Esophagus
• Bronchial Neoplasm
• Bronchial Neoplasms
• Constriction, Pathologic
• Esophageal Dysplasia
• Esophageal Neoplasm
• Esophageal Neoplasms
• Esophageal Stenosis
• Neoplasms
• Stenosis of Bronchus or Trachea

• NCT number: NCT01802203
• Study type: Observational [Patient Registry]
• Source: US Endoscopy Group Inc.
• Status: Completed
• Start date: April 2013
• Completion date: April 2022